Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb;174(2):P1-9.
doi: 10.1530/EJE-15-0873. Epub 2015 Nov 12.

GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults

D B Allen  1 , P Backeljauw  1 , M Bidlingmaier  1 , B M K Biller  1 , M Boguszewski  1 , P Burman  1 , G Butler  1 , K Chihara  1 , J Christiansen  1 , S Cianfarani  1 , P Clayton  1 , D Clemmons  1 , P Cohen  1 , F Darendeliler  1 , C Deal  1 , D Dunger  1 , E M Erfurth  1 , J S Fuqua  1 , A Grimberg  1 , M Haymond  1 , C Higham  1 , K Ho  1 , A R Hoffman  1 , A Hokken-Koelega  1 , G Johannsson  1 , A Juul  1 , J Kopchick  1 , P Lee  1 , M Pollak  1 , S Radovick  1 , L Robison  1 , R Rosenfeld  1 , R J Ross  1 , L Savendahl  1 , P Saenger  1 , H T Sorensen  1 , K Stochholm  1 , C Strasburger  1 , A Swerdlow  1 , M Thorner  1
Affiliations

GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults

D B Allen et al. Eur J Endocrinol. 2016 Feb.

Abstract

Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.

PubMed Disclaimer

References

    1. Rudge P, Jaumuktane Z, Adlard P, Bjurstrom N, Caine D, Lowe J, Norsworthy P, Hummerich H, Druyeh R, Wadsworth JD, et al. Iatrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years. Brain. 2015;138:3386–3399. doi: 10.1093/brain/awv235. - DOI - PMC - PubMed
    1. Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. Journal of Clinical Endocrinology and Metabolism. 2001;86:1868–1870. - PubMed
    1. Deodati A, Ferroli BB, Cianfarani S. Association between growth hormone therapy and mortality, cancer and cardiovascular risk: systematic review and meta-analysis. Growth Hormone & IGF Research. 2014;24:105–111. doi: 10.1016/j.ghir.2014.02.001. - DOI - PubMed
    1. Stochholm K, Johannsson G. Reviewing the safety of GH replacement therapy in adults. Growth Hormone & IGF Research. 2015;25:149–157. doi: 10.1016/j.ghir.2015.06.006. - DOI - PubMed
    1. Raman S, Grimberg A, Waguespack SG, Miller BS, Sklar CA, Meacham LR, et al. Risk of neoplasia in pediatric patients receiving growth hormone therapy – a report from the Pediatric Endocrine Society Drug and Therapeutics Committee. Journal of Clinical Endocrinology and Metabolism. 2015;100:2192–2203. doi: 10.1210/jc.2015-1002. - DOI - PMC - PubMed

Publication types